Mary Hames is a seasoned Medical Affairs executive with a proven track record of leading high-performing teams and delivering strategic impact across rare disease, diagnostics, and oncology. With a foundation in biochemical genetics and over a decade of industry experience, she has played pivotal roles in clinical operations, launch preparedness, and cross-functional leadership. Known for her ability to navigate complex medical landscapes, Mary has successfully built and led medical teams, advanced companion diagnostics, and driven field strategy across multiple therapeutic areas. Her leadership is marked by scientific rigor, operational excellence, and a deep commitment to improving outcomes for patients with rare and life-threatening conditions.

Jennifer T. Feldman, MBA, HTL (ASCP), QIHC, is a visionary healthcare business development leader with over 23 years of experience in oncology diagnostics, medical devices, and biotechnology. She has a proven track record of driving strategic partnerships, advancing innovative technologies, and optimizing commercial success in the healthcare industry. Jennifer’s expertise spans clinical pathology, research-use-only applications, and companion diagnostics, making her a key player in transforming patient care. With an MBA in International Business and certifications in histotechnology and immunohistochemistry, she seamlessly blends technical proficiency with business acumen. A sought-after speaker and industry expert, Jennifer is passionate about leveraging her knowledge and leadership to foster innovation, improve healthcare outcomes, and contribute to the future of medical advancements.